ImmunoCellular Therapeutics, Ltd to Present Clinical Data from ICT-107 at Leading Neurology Conference

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced that John S. Yu, M.D., the company’s Chief Scientific Officer and Chairman of the Board, will present clinical data from ICT-107, the company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM), at the 78th American Association of Neurological Surgeons (AANS) Annual Meeting at the Pennsylvania Convention Center in Philadelphia. Dr. Yu’s presentation, titled “Targeting Cancer Stem Cells”, is scheduled for today at 3:30 p.m. During the presentation, Dr. Yu will also present pre-clinical data from ICT-121, ImmunoCellular Therapeutics’ “off the shelf” therapeutic vaccine product candidate targeting cancer stem cells (CSC’s) for multiple cancer indications.